A Recurrent Activating Missense Mutation in Waldenström Macroglobulinemia Affects the DNA Binding of the ETS Transcription Factor SPI1 and Enhances Proliferation.
暂无分享,去创建一个
O. Elemento | P. Vyas | F. Cosset | O. Bernard | P. Dessen | C. Guillouf | P. Morel | N. Droin | E. Durot | V. Leblond | P. Cornillet‐Lefèbvre | J. Charbonnier | F. Pflumio | E. Verhoeyen | S. Aoufouchi | V. Ribrag | F. Nguyen‐Khac | V. Della-Valle | F. Charlotte | P. Rameau | T. Mercher | H. Ghamlouch | B. Stoilova | E. Mylonas | F. Damm | R. Haddad | M. Diop | V. Ropars | V. Camara-clayette | N. Azar | M. Armand | M. Metzner | D. Roos-Weil | Cécile Hérate | C. Decaudin | Diane Lara | V. Camara‐Clayette
[1] W. Shi,et al. Environmental sensing by mature B cells is controlled by the transcription factors PU.1 and SpiB , 2017, Nature Communications.
[2] Manolis Kellis,et al. Chromatin-state discovery and genome annotation with ChromHMM , 2017, Nature Protocols.
[3] D. Dunson,et al. Genetic and Functional Drivers of Diffuse Large B Cell Lymphoma , 2017, Cell.
[4] Aviad Tsherniak,et al. Somatic Superenhancer Duplications and Hotspot Mutations Lead to Oncogenic Activation of the KLF5 Transcription Factor. , 2017, Cancer discovery.
[5] S. Miyano,et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia , 2017, Nature Genetics.
[6] S. Nutt,et al. Genome-Wide Identification of Target Genes for the Key B Cell Transcription Factor Ets1 , 2017, Front. Immunol..
[7] P. Vyas,et al. Genetically distinct leukemic stem cells in human CD34− acute myeloid leukemia are arrested at a hemopoietic precursor-like stage , 2016, The Journal of experimental medicine.
[8] Martin A. Nowak,et al. Mutations driving CLL and their evolution in progression and relapse , 2015, Nature.
[9] G. Boucher,et al. The transcriptomic landscape and directed chemical interrogation of MLL-rearranged acute myeloid leukemias , 2015, Nature Genetics.
[10] K. Basso,et al. Germinal centres and B cell lymphomagenesis , 2015, Nature Reviews Immunology.
[11] R. DeKoter,et al. Genome-wide comparison of PU.1 and Spi-B binding sites in a mouse B lymphoma cell line , 2015, BMC Genomics.
[12] Wei Shi,et al. The transcription factors IRF8 and PU.1 negatively regulate plasma cell differentiation , 2014, The Journal of experimental medicine.
[13] C. Abreu-Goodger,et al. The miR-155–PU.1 axis acts on Pax5 to enable efficient terminal B cell differentiation , 2014, The Journal of experimental medicine.
[14] Paul Shinn,et al. Blockade of oncogenic IκB kinase activity in diffuse large B-cell lymphoma by bromodomain and extraterminal domain protein inhibitors , 2014, Proceedings of the National Academy of Sciences.
[15] Satoru Miyano,et al. Acquired initiating mutations in early hematopoietic cells of CLL patients. , 2014, Cancer discovery.
[16] B. Beutler,et al. Consequences of the recurrent MYD88L265P somatic mutation for B cell tolerance , 2014, The Journal of experimental medicine.
[17] W. Chan,et al. Deregulation of ETS1 and FLI1 contributes to the pathogenesis of diffuse large B-cell lymphoma. , 2013, Blood.
[18] S. Chevret,et al. Chromosomal aberrations and their prognostic value in a series of 174 untreated patients with Waldenström's macroglobulinemia , 2013, Haematologica.
[19] L. Garrett-Sinha. Review of Ets1 structure, function, and roles in immunity , 2013, Cellular and Molecular Life Sciences.
[20] N. Harris,et al. MYD88 L265P somatic mutation in Waldenström's macroglobulinemia. , 2012, The New England journal of medicine.
[21] Emmanuel Barillot,et al. Spi-1/PU.1 activates transcription through clustered DNA occupancy in erythroleukemia , 2012, Nucleic acids research.
[22] Paul Shinn,et al. Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. , 2012, Cancer cell.
[23] P. Opolon,et al. TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.
[24] Peter C. Hollenhorst,et al. Genomic and biochemical insights into the specificity of ETS transcription factors. , 2011, Annual review of biochemistry.
[25] Joseph M. Connors,et al. Oncogenically active MYD88 mutations in human lymphoma , 2011, Nature.
[26] L. Garrett-Sinha,et al. Regulation of Follicular B Cell Differentiation by the Related E26 Transformation-Specific Transcription Factors PU.1, Spi-B, and Spi-C , 2010, The Journal of Immunology.
[27] Andrew R. Gehrke,et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo , 2010, The EMBO journal.
[28] J. Crowley,et al. International prognostic scoring system for Waldenstrom macroglobulinemia. , 2009, Blood.
[29] A. Baruchel,et al. Activating mutations in human acute megakaryoblastic leukemia. , 2008, Blood.
[30] G. Gilkeson,et al. The Transcription Factor Fli-1 Modulates Marginal Zone and Follicular B Cell Development in Mice1 , 2008, The Journal of Immunology.
[31] Harinder Singh,et al. Gene regulatory networks directing myeloid and lymphoid cell fates within the immune system. , 2008, Seminars in immunology.
[32] L. Garrett-Sinha,et al. Ets-1 Regulates Plasma Cell Differentiation by Interfering with the Activity of the Transcription Factor Blimp-1* , 2008, Journal of Biological Chemistry.
[33] W. Leonard,et al. The transcription factor GABP is a critical regulator of B lymphocyte development. , 2007, Immunity.
[34] L. Staudt,et al. Aberrant immunoglobulin class switch recombination and switch translocations in activated B cell–like diffuse large B cell lymphoma , 2007, The Journal of experimental medicine.
[35] L. Staudt,et al. A library of gene expression signatures to illuminate normal and pathological lymphoid biology , 2006, Immunological reviews.
[36] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.
[37] S. Nutt,et al. Oncogenes and Tumor Suppressors (795 articles) Plenary Papers (356 articles) , 2004 .
[38] C. Foulds,et al. Ras/Mitogen-Activated Protein Kinase Signaling Activates Ets-1 and Ets-2 by CBP/p300 Recruitment , 2004, Molecular and Cellular Biology.
[39] J. Kutok,et al. Acute myeloid leukemia induced by graded reduction of a lineage-specific transcription factor, PU.1 , 2004, Nature Genetics.
[40] M. Dimopoulos,et al. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. , 2003, Seminars in oncology.
[41] G. Blobel,et al. Inhibition of CBP-Mediated Protein Acetylation by the Ets Family Oncoprotein PU.1 , 2002, Molecular and Cellular Biology.
[42] A. Sharrocks. The ETS-domain transcription factor family , 2001, Nature Reviews Molecular Cell Biology.
[43] B. Graves,et al. Phosphorylation represses Ets-1 DNA binding by reinforcing autoinhibition. , 2000, Genes & development.
[44] A. Brass,et al. Assembly requirements of PU.1–Pip (IRF‐4) activator complexes: inhibiting function in vivo using fused dimers , 1999, The EMBO journal.
[45] F. Moreau-Gachelin,et al. The Transcription Factor Spi-1/PU.1 Binds RNA and Interferes with the RNA-binding Protein p54(*) , 1996, The Journal of Biological Chemistry.
[46] F. Moreau-Gachelin,et al. DNA binding specificities of Spi-1/PU.1 and Spi-B transcription factors and identification of a Spi-1/Spi-B binding site in the c-fes/c-fps promoter. , 1995, Oncogene.
[47] E. Scott,et al. Requirement of transcription factor PU.1 in the development of multiple hematopoietic lineages. , 1994, Science.
[48] Razvan R. Popovici,et al. Additional file 8 , 2010 .
[49] M. Minden,et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. , 2002, Blood.
[50] K. Nakayama,et al. Transcription Factor PU.1 Represses and Activates Gene Expression in Early T Cells by Redirecting Partner Transcription Factor Binding , 2018, Immunity.